Skip to the reading

[American Peptide Supply](/)

Four chapters on the supply picture

- [01 The change](/#the-change)

- [02 The history](/#the-history)

- [03 Who does what](/#who-does-what)

- [04 Keeping care](/#keeping-care)

A U.S. supply guide · Read on 27 October 2026

# Keeping care going after a shortage ends

A shortage ending can leave questions about your next prescription. Here’s where the national picture meets your own plan.

## The public date and your next week

A national announcement has a date. Your care has a different calendar: the next appointment, a work shift, a prescription that hasn’t been filled. We think the explanation needs room for both.

FDA’s [shortage explanation](https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages) concerns supply and demand across the country. Local problems can remain after a national shortage ends. “Resolved” can be true while your week is still difficult.

### National shortage

FDA looks at whether U.S. supply meets demand, including projected demand. That finding doesn’t tell you what’s available at one pharmacy.

## Give the conversation somewhere to begin

For a personal plan, the route is a licensed U.S. clinician who can prescribe. That can be in person or through lawful telehealth. This guide can help with the background for that conversation.

Three questions give it somewhere useful to go: What changed in the shortage record? What does that mean for my plan? Who can explain the next step if the expected medicine isn’t available?

The pharmacist can explain a preparation and its instructions. The prescribing clinician can assess a change in treatment. A clear plan connects those two conversations instead of leaving you to join the dots alone.

![Two facing chairs in an unoccupied consultation room with a closed door and a desk to one side.](/aps-calendar-3ef9e129bd73/room-for-a-conversation.webp)

A prescription interruption belongs in a personal care conversation. Your clinician can assess a treatment change; the national date supplies the background.

## Check the medicine, form and date

FDA’s [shortage page explains how to search by generic name](https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages). Its [database separates current shortages, resolved shortages and discontinuations](https://www.accessdata.fda.gov/scripts/drugshortages/). A notice about one form doesn’t settle the status of another.

An old announcement can explain what happened then. It can’t tell you what every location has today. Keeping its date attached saves a lot of confusion.

FDA’s [Drug Shortage Staff](https://www.fda.gov/drugs/drug-shortage-staff), the team handling shortage information, receives regular updates from manufacturers. The database is the place to revisit a question about national supply.

### Discontinuation

A product is leaving the market. That is a different entry from a national shortage.

## A changed preparation needs a clear explanation

FDA’s [July 2024 semaglutide alert](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded) described reports of dosing errors with compounded injections, some involving hospital care. Different concentrations and confusion over measurement units were among the problems FDA described.

Questions about a new preparation’s instructions belong with the pharmacist and prescribing clinician. This guide has no dose conversions or restart directions.

FDA recommends an [approved medicine when available and appropriate](https://www.fda.gov/drugs/human-drug-compounding/compounding-when-drugs-are-fdas-drug-shortages-list). Compounded medicines are not FDA-approved. Keeping that difference clear is part of understanding the next step.

## Sources for this reading

- [Frequently Asked Questions about Drug Shortages](https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages)

- [Drug Shortages — search and reporting routes](https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages)

- [FDA Drug Shortages database](https://www.accessdata.fda.gov/scripts/drugshortages/)

- [Drug Shortage Staff](https://www.fda.gov/drugs/drug-shortage-staff)

- [FDA alert about dosing errors with compounded injectable semaglutide](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded)

- [Compounding when Drugs are on FDA’s Drug Shortages List](https://www.fda.gov/drugs/human-drug-compounding/compounding-when-drugs-are-fdas-drug-shortages-list)

Read on 27 October 2026. [All readings and their context](/references).

[Return to the sequence of public decisions](/shortage-calendar)

We follow the supply calendar as a guide; we are neither a clinic nor a pharmacy, and we sell nothing.

[References](/references)

[About](/about)

[Contact](/contact)

© 2026 American Peptide Supply